Disability progression in relapsing forms of multiple sclerosis (MS) tends to follow one of four distinct patterns, according to…
Marisa Wexler, MS
Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Marisa Wexler, MS
Myelin, the protective coating that helps nerve signals travel quickly and efficiently, also plays a key role in the precise…
A clinical trial testing whether music therapy can make botulinum toxin injections for spasticity more tolerable for people with…
Following negative Phase 3 trial results, Sanofi announced that it will not be pursuing approval of its experimental therapy…
A signaling molecule called erythropoietin (EPO) plays a key role in allowing the immune system to distinguish the body’s own…
A few months ago in Barcelona, at the annual conference of the European Committee for Treatment and Research in Multiple…
Disability progression is not always permanent for people with relapsing-remitting multiple sclerosis (RRMS), even when it occurs independent of…
Oligodendrocytes, the cells that build and repair myelin in the brain and spinal cord, may play a role in the…
Simultaneously measuring levels of two blood proteins — glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL)…
A Phase 2 clinical trial testing PIPE-307, an experimental therapy designed to support myelin repair in people with multiple…
A clinical trial is now recruiting participants to test whether an experimental vaccine for the Epstein-Barr virus (EBV) is…
Mesenchymal stem cell therapy shows promise for treating multiple sclerosis (MS), with improvements seen in disability, walking ability,…
A new technique is letting scientists peer into the brain’s wiring with greater detail by simply using a microscope and…
Genentech‘s experimental oral therapy fenebrutinib has become the first Bruton’s tyrosine kinase (BTK) inhibitor to show positive Phase…
A new wearable brain-mapping tool could dramatically change how doctors monitor people with multiple sclerosis (MS), making it easier…
Researchers have developed a highly sensitive imaging technique that can detect damage to myelin, the fatty wrapping around nerve…
Ultraviolet light therapy may help reduce inflammation and disease severity in people with multiple sclerosis (MS), according to data…
People with multiple sclerosis (MS) tend to have high levels of antibodies targeting the Epstein-Barr virus (EBV), but…
People living with multiple sclerosis (MS) have consistently lower quality of life than the general population — regardless of…
A third of adults live with chronic physical conditions such as multiple sclerosis (MS), but in most cases these…
Eating more carbohydrates is significantly associated with a higher risk of developing multiple sclerosis (MS), particularly among women and…
People with multiple sclerosis (MS) have altered levels of bacteria in their mouths, with reduced levels of normal healthy…
Signs of myelin damage are detectable about one year before damage to nerve fibers is apparent and about seven years…
Abnormal brain cells, known as disease-associated radial glia or DARGs, may play a key role in driving chronic inflammation in…
Seizures in people with multiple sclerosis (MS) may be driven by changes in levels of certain brain signaling molecules,…
Researchers have identified two experimental medications that may promote myelin repair in people with multiple sclerosis (MS). The two…
Zenas Biopharma has acquired global rights to develop the BTK inhibitor orelabrutinib to treat multiple sclerosis (MS) and…
Up to six years of continuous treatment with Briumvi (ublituximab) led to sustained reductions in relapse rates and a…
Increasing the dose of Ocrevus (ocrelizumab) by two- or threefold, depending on a person’s weight, did not provide additional…
Most people with relapsing forms of multiple sclerosis (MS) given Mavenclad (cladribine) did not experience confirmed disability progression…